Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 is involved in cognitive brain function and learning, 98”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [98]
In the citing paper
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85,86,87].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [86]
In the citing paper
“They are involved in multiple biological pathways that could be beneficial in AD including improvement of BBB integrity and vascular health, promotion of homeostasis in microglia and astrocytes, positive effects on adaptative immune cells (including natural killer cells and activated regulatory T cells), improvement of synaptic viability, and neuroprotection [17–26].”
In the citing paper
“Preclinical results in murine models treated with GLP-1RAs suggest that the potential effects of semaglutide in AD may be exerted via impact on several AD-related pathophysiologic processes including neuroinflammatory pathways, vascular and BBB integrity, reduced synaptic loss, and neuroprotection [19, 21, 23–26, 46–48];”
Citations
Cites
Modification of seizure activity by electrical stimulation: II. Motor seizure
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90177-0 · Cited by 7,171
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
The molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Indeed, GLP-1 exerts effects on glucose-dependent insulin secretion, insulin biosynthesis, gastrointestinal motility, islet b-cell neogenesis, energy homeostasis and food intak”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 1×
“Immunohistochemical comparison of the CA3 subregion of the hippocampus using Fluorojade-B, a fluorochrome stain specific for degenerating neuron”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationEnvironmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
Young, D., Lawlor, P. A., Leone, P., Dragunow, M., & During, M. J. (1999) · Nature Medicine · doi:10.1038/7449 · Cited by 732
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citation
Cited by
Items 601–700 of 859
What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson’s Disease?
Xue, J., Tao, K., Wang, W., & Wang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031641 · Cited by 20
Riemma, M. A., Mele, E., Donniacuo, M., Telesca, M., Bellocchio, G., Castaldo, G., Rossi, F., Angelis, A. D., Cappetta, D., Urbanek, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422740 · Cited by 15
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Orozco‐Beltrán, D., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española · doi:10.1016/j.rce.2015.07.003 · Cited by 21
Iashchishyn, I. A., Алексеевна, Г. М., Moskalenko, R., Davydova, T. V., Wang, C., Sewell, R. D. E., & Morozova‐Roche, L. A. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00512 · Cited by 13
Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy
Zhou, Y., Li, Z., Cao, X., Ma, H., White, P. F., Xu, X., Jiang, Y., Sun, X.-J., & Cui, Y. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.007 · Cited by 14
Jones, S., Hyde, A., & Davidson, T. L. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.05.001 · Cited by 18
D‐Ser2‐oxyntomodulin ameliorated Aβ31‐35‐induced circadian rhythm disorder in mice
Wang, L., Zhao, J., Wang, C., Hou, X., Ning, N., Sun, C., Guo, S., Yuan, Y., Lin, L., Hölscher, C., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13211 · Cited by 13
Llach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 21
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 15
Hui, Y., Kuang, L., Zhong, Y., Tang, Y., Xu, Z., & Zheng, T. (2023) · iScience · doi:10.1016/j.isci.2023.108689 · Cited by 14
Davidy, T., Yore, I., Cukierman‐Yaffe, T., Ravona‐Springer, R., Livny, A., Lesman‐Segev, O. H., Azuri, Y., Carmichael, O. T., Kapogiannis, D., Zetterberg, H., et al. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111898 · Cited by 15
Ma, L., Liu, S.-F., Ma, Z.-Q., Guo, Y.-G., Li, M., Gao, Y., Wen, Y., Niu, Y., Sui, H.-X., Li, B.-S., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0723 · Cited by 13
Das, A., Geetha, K. M., & Hazarika, I. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09927-y · Cited by 12
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
Ahn, K.-C., Learman, C. R., Baker, G. B., Weaver, C. L., Chung, P., Kim, H., & Song, M.-S. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e297 · Cited by 14
Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells
Wallrapp, C., Thoenes, E., Thürmer, F., Jork, A., Kassem, M. S., & Geigle, P. (2012) · Journal of Microencapsulation · doi:10.3109/02652048.2012.726281 · Cited by 13
The role of the GLP-1/GLP-1R signaling pathway in regulating seizure susceptibility in rats
Zhang, Y., Fang, J., Feng, W., Sun, Q., Xu, J., & Xia, Q. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.017 · Cited by 14
Oral Galactose Provides a Different Approach to Incretin-Based Therapy of Alzheimer's Disease
Šalković‐Petrišić, M. (2018) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2018/4.1204 · Cited by 12
García‐Casares, N., García-Arnés, J. A., Gómez‐Huelgas, R., Valdivielso, P., García-Arias, C., & González‐Santos, P. (2014) · Revista de Neurología · doi:10.33588/rn.5911.2014023 · Cited by 16
de Sousa, É., Sparks, L. M., & Townsend, K. L. (2025) · Diabetes · doi:10.2337/db25-0158 · Cited by 13
Scheltens, P., Atri, A., Feldman, H., Zetterberg, H., Sano, M., Johannsen, P., León, T., Bardtrum, L., Jeppesen, R., Hansen, C. T., et al. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70200 · Cited by 25
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
Glucagon-like peptide 1 receptor
Hoersch, D., Schrader, J., & Goeke, R. (2005) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a001042.01 · Cited by 11
Musci, P., Colella, M., Fanelli, F., Altomare, A., Pisano, L., Carlucci, C., Luisi, R., & Degennaro, L. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00614 · Cited by 11
El‐Deeb, O. S., Soliman, G. M., & El‐Esawy, R. O. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22541 · Cited by 15
Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death
Ahn, Y. J., Shin, H.-J., Jeong, E.-A., An, H. S., Lee, J.-Y., Jang, H., Kim, K., Lee, J., Shin, M. C., & Roh, G. S. (2021) · Cells · doi:10.3390/cells10102527 · Cited by 12
Nakajima, S., Numakawa, T., Adachi, N., Yoon, H. S., Odaka, H., Ooshima, Y., & Kunugi, H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.052 · Cited by 12
Repurposing GLP1 agonists for neurodegenerative diseases
Markaki, I., Winther, K., Catrina, S., & Svenningsson, P. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.007 · Cited by 14
The pathogenesis of obesity: Stress and the brain-gut axis
Kral, J. G. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2004.12.009 · Cited by 14
Genetic Dissection of Learning and Memory in Mice
Mineur, Y. S., Crusio, W. E., & Sluyter, F. (2004) · Neural Plasticity · doi:10.1155/np.2004.217 · Cited by 13
Sarro, C. D., Tallarico, M., Pisano, M., Gallelli, L., Citraro, R., Sarro, G. D., & Leo, A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175098 · Cited by 10
Translational research on cognitive impairment in chronic kidney disease
Wagner, C. A., Massy, Z. A., Capasso, G., Mattace-Raso, F., Pépin, M., Bobot, M., Zoccali, C., Ferreira, A. C., Hoorn, E. J., Silva, P. H. I., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae229 · Cited by 16
Ohshima, R., Hotsumi, K., Holscher, C., & Seki, K. (2015) · American Journal of BioScience · doi:10.11648/j.ajbio.20150301.13 · Cited by 12
The role of glucagon‑like peptide 1 in glucose homeostasis and in other aspects of human physiology
Franek, E., Gajos, G., Gumprecht, J., Kretowski, A. J., Zahorska‐Markiewicz, B., & Malecki, M. T. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.829 · Cited by 14
Tang, Y., Yang, K., Zhao, J., Liang, X., & Wang, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00456 · Cited by 10
Giorgino, F., Natalicchio, A., Leonardini, A., & Laviola, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.022 · Cited by 11
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Hölscher, C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.007 · Cited by 15
Nakamura, M., & Krauss, J. K. (2016) · Neurosurgery · doi:10.1227/neu.0000000000001210 · Cited by 10
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 12
Self-citationGLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 17
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 9
Alteration of brain nuclei in obese children with and without Prader-Willi syndrome
Wu, N., Yu, H., & Xu, M. (2022) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2022.1032636 · Cited by 10
Siskind, D. J., Baker, A., Russell, A. W., Warren, N., Robinson, G., Parker, S., Medland, S. E., Kisely, S. R., Hager, T., & Arnautovska, U. (2023) · BJPsych Open · doi:10.1192/bjo.2023.532 · Cited by 11
GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner
Trammell, T. S., Henderson, N. L., Madkour, H. S., Stanwood, G. D., & Graham, D. L. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04910-8 · Cited by 10
Erbaş, O., Saraç, F., Aktuğ, H., & Peker, G. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/946265 · Cited by 9
Silva, M. F. P., Alves, P. L., Alponti, R. F., Silveira, P. F., & Abdalla, F. M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113630 · Cited by 10
Bariatric Surgery and Gut-Brain-Axis Driven Alterations in Cognition and Inflammation
Custers, E., Franco, A., & Kiliaan, A. J. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s437156 · Cited by 9
Semaglutide attenuates neuroinflammation in male mice
Rausch, D. M., Ludwig, M. Q., Bentsen, M. A., Hansen, S. N., Secher, A., Holst, D., Moreno, J., Das, V., Egerod, K. L., Bjerregaard, A.-M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74038-4 · Cited by 10
Wang, X.-C., Chu, C.-L., Li, H.-C., Lu, K., Liu, C.-J., Cai, Y., Quan, S., & Zhang, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1018027 · Cited by 10
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
Steiner, A., Owen, B. M., Bauer, J. P., Seanez, L., Kwon, S., Biddinger, J. E., Huffman, R., Ayala, J. E., Nobis, W. P., & Lewis, A. S. (2022) · Hippocampus · doi:10.1002/hipo.23469 · Cited by 8
Hasan, M. A., Schwartz, S. S., McKenna, V., & Ing, R. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06758-1 · Cited by 7
Rossetti, P., Porcellati, F., Lucidi, P., Ricci, N. B., Candeloro, P., Cioli, P., Santeusanio, F., Bolli, G. B., & Fanelli, C. G. (2008) · Diabetes · doi:10.2337/db08-0641 · Cited by 9
Functional Characterization of N‐Terminally GFP‐Tagged GLP‐1 Receptor
Bavec, A., & Ličar, A. (2009) · BioMed Research International · doi:10.1155/2009/498149 · Cited by 8
INTRAVITREAL CELL-BASED PRODUCTION OF GLUCAGON-LIKE PEPTIDE-1
Zhang, R., Zhang, H., Xu, L., Ma, K., Wallrapp, C., & Jonas, J. B. (2010) · Retina · doi:10.1097/iae.0b013e3181f27509 · Cited by 8
Endocrine dysfunction and cognitive impairment
Calsolaro, V., Bottari, M., Coppini, G., Lemmi, B., & Monzani, F. (2021) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03295-2 · Cited by 10
The GLP-1 Concept in the Treatment of Type 2 Diabetes—Still Standing at the Gate of Dawn?
Schmitz, O. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2750 · Cited by 11
Ma, H., Chang, Z., Sun, H., Ma, D., Li, Z., Li, H., Zhang, Z., Hölscher, C., & Zhang, Z. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05037-7 · Cited by 7
Zoicas, I., Mühle, C., von Hörsten, S., Plank, A.-C., & Kornhuber, J. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02146-8 · Cited by 7
Xu, T., Zheng, Y. J., Wong, S., Dri, C. E., Zhou, X. T., Teopiz, K. M., Le, G. H., & McIntyre, R. S. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104870 · Cited by 12
The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.30 · Cited by 7
Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage
Siddiqui, E. M., Mehan, S., Bhalla, S., & Shandilya, A. (2022) · Current Research in Neurobiology · doi:10.1016/j.crneur.2022.100055 · Cited by 6
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 9
Hartsock, M. J., Strnad, H. K., & Spencer, R. L. (2021) · Journal of Biological Rhythms · doi:10.1177/07487304211058256 · Cited by 8
Allosteric modulators targeting GPCRs
López-Rodríguez, M. L., Benhamú, B., & Vázquez‐Villa, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00011-8 · Cited by 10
Predictive Value of Gut Microbiome for Cognitive Impairment in Patients with Hypertension
Lu, S., Shao, L., Zhang, Y., Yang, Y., Wang, Z., Zhang, B., Yu, J. Z., Xu, Q., Wang, S., Chen, X., et al. (2021) · Disease Markers · doi:10.1155/2021/1683981 · Cited by 8
Molecular network of obesity: what does it promise for pharmacotherapy?
Myslobodsky, M. S. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00424.x · Cited by 7
Aguggia, J. P., Fernández, G., Cassano, D., Mustafá, E. R., Rodríguez, S., Cantel, S., Fehrentz, J., Raingo, J., Schiöth, H. B., Habib, A. M., et al. (2024) · Endocrinology · doi:10.1210/endocr/bqae160 · Cited by 6
Cardiometabolic index and major depressive disorder: Stroke and diabetes as mediators
Liu, Z., & Zhai, G. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111340 · Cited by 9
Molecular mechanisms underlying obesity-induced memory dysfunction: a comprehensive narrative review
Golkar, A., Razazpour, F., Dalfardi, M., & Baghcheghi, Y. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115119 · Cited by 8
Wu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 9
Wang, Y., Song, X., Wang, Y., & Wang, N. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.10.094 · Cited by 6
Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics
Osaka, H., Nishida, K., & Kanazawa, T. (2024) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.185 · Cited by 12
Yang, Y., Song, L., Yu, L., Zhang, J., & Zhang, B. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5497 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Sundararaman, L. V., Gouda, D., Kumar, A., Sundararaman, S., & Goudra, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061978 · Cited by 7
Zubareva, O. E., & Melik-Kasumov, T. B. (2021) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093021040013 · Cited by 7
Sobral, M. V. S., Soares, V. G., Moreira, J. L. D. M. L., Rodrigues, L. K., Rocha, P., Bendaham, L. C. A. R., Gonçalves, O. R., Pirolla, R. D. C., Vilela, L. V., de Abreu, V. S., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107210 · Cited by 6
Virtuoso, A., Forkman, B., Sarruf, D. A., Tveden‐Nyborg, P., & Sørensen, D. B. (2017) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2017.10.012 · Cited by 6
The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
Ferrari, F., Moretti, A., & Villa, R. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105018 · Cited by 6
Hanna, A., Connelly, K. A., Josse, R. G., & McIntyre, R. S. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.972370 · Cited by 6
Glucagon like peptide-1: A new therapeutic target for diabetes mellitus
Patel, S., Goyal, R., Anand, I., Shah, J., Patel, H., & Patel, C. (2006) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.27018 · Cited by 7
Intraocular cell‐based production of glucagon‐like peptide‐1 in the anterior chamber
Zhang, R., Ma, K., Xu, L., Wallrapp, C., & Jonas, J. B. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01762.x · Cited by 6
Kajitani, Y., Miyazawa, T., Inoue, T., Kajitani, N., Fujita, M., Takeichi, Y., Miyachi, Y., Sakamoto, R., & Ogawa, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0296006 · Cited by 5
Beyond glycemic control: the neuroprotective potential of tirzepatide
Hristov, M., Cheema, G., Ali, H., & Andreeva-Gateva, P. A. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e155150 · Cited by 7
Schechter, M., Fishkin, A., Mosenzon, O., Sehtman-Shachar, D. R., Cukierman‐Yaffe, T., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02962-8 · Cited by 10
Pinto, L. F., & Guerreiro, C. A. M. (2026) · Seizure · doi:10.1016/j.seizure.2026.05.013 · Cited by 5
Du, Y., Sun, C., Wu, L., Wu, Z., Tong, Y., Tian, H., Mao, Y., Shi, X., Ding, H., Xie, W., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.05.014 · Cited by 8
Davidy, T., Yore, I., Cukierman‐Yaffe, T., Ravona‐Springer, R., Livny, A., Lesman‐Segev, O. H., Azuri, Y., Carmichael, O. T., Kapogiannis, D., Zetterberg, H., et al. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111825 · Cited by 5
RetractedActivation of glucagon‐like peptide‐1 receptors and skilled reach foraging
Vestlund, J., Bergquist, F., Licheri, V., Adermark, L., & Jerlhag, E. (2020) · Addiction Biology · doi:10.1111/adb.12953 · Cited by 8
Banks, W. A., Calias, P., Hansen, K. M., Bullock, K. M., & Engelke, K. J. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac001 · Cited by 7
Self-citationExercise Improves Spatial Learning and Memory Performance through the Central GLP-1 Receptors
Taati, M., Barzegar, P. E. F., & Raisi, A. (2022) · Behavioural Neurology · doi:10.1155/2022/2900628 · Cited by 6
Rebelos, E., Malloggi, E., Parenti, M., Dardano, A., Tura, A., & Daniele, G. (2023) · Metabolites · doi:10.3390/metabo13070814 · Cited by 6
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease
Crook, H., & Edison, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240730 · Cited by 6
Dipeptidyl peptidase-4 inhibitors enhance memory retention via neuropeptide Y
Zoicas, I., von Hörsten, S., Plank, A.-C., & Kornhuber, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177556 · Cited by 7
Exendin-4 effects on islet volume and number in mouse pancreas
Khorsandi, L., & Nejaddehbashi, F. (2013) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502013000400014 · Cited by 5
Lee, C. H., Yoo, K., Ryu, P. D., Park, J. H., Choi, J. H., Kim, S., Hwang, I. K., Kim, Y., & Won, M. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9632-7 · Cited by 5
Bavec, A. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9813-y · Cited by 5
Maul, B., Becker, M., Gembardt, F., Becker, A., Schultheiss, H., Siems, W., & Walther, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050187 · Cited by 5
Incretins: the novel therapy of type 2 diabetes.
Thongtang, N., & Sriwijitkamol, A. (2008) · PubMed · Cited by 6
Gut Hormones Restrict Neurodegeneration in Parkinson’s Disease
Bayliss, J., Stark, R., Reichenbach, A., & B., Z. (2011) · Advanced Understanding of Neurodegenerative Diseases · doi:10.5772/28028 · Cited by 5
Antiaging methods and medicines for the memory
Banks, W. A., & Farr, S. A. (2004) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2004.02.007 · Cited by 5
Self-citation
Metadata
- Authors
- During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., & Haile, C. N.
- Affiliations
- University of Auckland (NZ)
- Thomas Jefferson University (US)
- St. Louis VA Medical Center (US)
- University of Toronto (CA)
- Corresponding author
- During, Matthew J
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-08-17
- Volume
- 9
- Issue
- 9
- Pages
- 1173-1179
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2124852816
- Cited by
- 851
- References
- 42
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 50 · 2023: 39 · 2022: 58 · 2021: 53 · 2020: 44 · 2019: 36 · 2018: 37 · 2017: 39 · 2016: 34 · 2015: 54 · 2014: 46 · 2013: 47 · 2012: 43
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Marsden Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, associative learning, spatial learning, memory, hippocampus, neuroprotection, kainate-induced seizures, neuronal apoptosis, cognitive enhancement, gut-brain signaling
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Administration, Intranasal, Amino Acid Sequence, Animals, Behavior, Animal, Cognition, Glucagon, Hippocampus, Kainic Acid, Learning, Male, Molecular Sequence Data, Neurons, Peptide Fragments, Protein Precursors, Seizures, Signal Transduction, Gene Expression, Rats, Sprague-Dawley, Apoptosis, Sequence Homology, Amino Acid, Gene Transfer Techniques, Receptors, Glucagon, Mice, Knockout, Neuroprotective Agents, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.